Flow cytometry analyzing the proportion of CD3+, CD4+ and CD8+ T cells in tumor tissue further confirmed that αMSLN treatment could significantly enhance the infiltration of CD3+CD8+ T cells (p = 0.0011) but not the CD3+CD4+ T cells (Figure 1M–P). The gene discussed is CD8A; the disease is neoplasm.